Papers

3

Total Citations

107

H-Index

2

About

Azik Hoffman is a urologic surgeon and researcher whose work centers on improving the diagnosis and surgical management of prostate, kidney, and bladder cancers. His most influential study, cited over 100 times, investigates the role of PSA density in stratifying prostate cancer risk, demonstrating how prostate volume impacts the detection of clinically significant disease—a contribution that helps reduce unnecessary biopsies and overtreatment. Hoffman has also advanced surgical safety in nephron-sparing procedures, evaluating the efficacy of biological hemostatic agents like Starsil® in robotic partial nephrectomy to minimize perioperative bleeding. More recently, his research on robotic radical cystectomy examines how neoadjuvant chemotherapy affects short-term surgical outcomes in bladder cancer patients, providing critical data for treatment planning. With a growing citation footprint and a focus on evidence-based, patient-centered urologic oncology, Hoffman’s work bridges the gap between diagnostic precision and surgical innovation, offering practical insights for clinicians managing complex genitourinary malignancies.

Research Focus

Key Achievements

2
H-Index
3
Papers
107
Total Citations
36
Avg Citations/Paper
🏆 Most Cited Paper
Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume
103 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Rambam Health Care Campus, Technion – Israel Institute of Technology

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 16 days ago